# Critical Evaluation of PIKFYVE Inhibition and Protein Clearance via Exocytosis Hypotheses
## Preliminary Context: PIKFYVE Biology and Mechanism
Before evaluating individual hypotheses, a fundamental mechanistic tension pervades all seven proposals: PIKFYVE generates PI(3,5)P2, and its inhibition is well-documented to impair autophagosome-lysosome fusion (PMID: 15548221). PIKFYVE inhibition typically causes cytoplasmic vacuolation and blocks the terminal step of autophagy (PMID: 22990836). For aggregate clearance to occur via exocytosis under these conditions, aggregates must be actively diverted to secretion pathways rather than accumulating in blocked autolysosomes. This prerequisite is insufficiently addressed across all seven hypotheses.
The therapeutic context is also relevant: PIKFYVE inhibitors (e.g., apilimod) were originally developed as anti-cancer agents (PMID: 26839307), with more recent work suggesting potential in neuroprotection, but the primary literature on ALS motor neuron models (PMID: 36754049) is limited.
---
## Hypothesis 1: TMED10 CUPS Pathway
### Specific Weaknesses
**1. Substrate mismatch between TMED10 capacity and aggregate properties.** The foundational CUPS study (PMID: 31722219) demonstrated TMED10-mediated secretion of soluble, leaderless proteins (fibroglobin, ACBD2) in HeLa cells under proteostatic stress. Aggregated proteins are, by definition, insoluble and physically larger than what a ~1nm pore (PMID: 31722219) could translocate. The TMED10 channel was never demonstrated to handle oligomeric or aggregated substrates.
**2. PI(3,5)P2-TMED10 link is entirely inferred.** The hypothesis proposes that PI(3,5)P2 depletion on ERGIC membranes "activates" TMED10, but no lipid-binding domain for TMED10 has been characterized, and no study has demonstrated PI(3,5)P2 as a direct regulator of TMED10 channel activity.
**3. CUPS pathway not validated in motor neurons.** The CUPS pathway was characterized in HeLa cells and confirmed in hepatocytes. Motor neurons have distinct secretory pathway biology, and no study has validated CUPS components (TMED10, SAR1B) in primary motor neuron secretion.
### Counter-Evidence
**1. TMED10 mutations cause protein trafficking disorders, not enhanced secretion.** TMED10 mutations have been associated with defects in GPI-anchor protein trafficking and congenital disorders of glycosylation (PMID: 29395064), which would be consistent with impaired rather than enhanced unconventional secretion.
**2. COPII components remain essential even in unconventional secretion.** Recent studies indicate that even unconventional secretion pathways require COPII coat components for vesicle formation (PMID: 31722219), contradicting the model of TMED10 acting independently for aggregate export.
**3. PIKFYVE inhibition causes ER stress, which typically *downregulates* TMED10.** The UPR activated by PIKFYVE inhibition (PMID: 28704975) is associated with global translation attenuation, which would reduce protein flux through TMED10 rather than increase it.
### Alternative Explanations
- **ER-phagy receptors** (FAM134B, RTN3) could deliver ER portions containing aggregates to autophagosomes for lysosomal degradation (PMID: 30104642), not secretion.
- PIKFYVE inhibition may cause **lysosomal membrane permeabilization**, releasing proteases into the cytoplasm that degrade aggregates (PMID: 31800846).
- **Intercellular transfer via tunneling nanotubes** (not exocytosis) could explain aggregate spreading/clearance between cells (PMID: 28656955).
### Key Experiments to Falsify
1. **In vitro TMED10 channel reconstitution:** Purify TMED10, proteoliposomes with PI(3,5)P2 or not, and assess whether aggregated TDP-43/FUS can be translocated. If aggregates cannot traverse the channel *in vitro*, the hypothesis fails.
2. **TMED10 knockout in motor neuron-astrocyte co-cultures:** If TMED10 deletion blocks therapeutic benefit of PIKFYVE inhibition, the hypothesis is supported. If motor neuron aggregates clear despite TMED10 knockout (with exosomes or alternative pathways compensating), the hypothesis is falsified.
3. **Live-cell imaging of aggregate secretion:** Tag aggregates with pHluorin (fluorescent only when extracellular) and monitor whether PIKFYVE inhibition increases pHluorin signal in a TMED10-dependent manner.
### Revised Confidence: 0.31
*Rationale: TMED10 has no demonstrated capacity for aggregated substrates, and the PI(3,5)P2-TMED10 link is purely speculative with no biochemical validation. The hypothesis conflates soluble unconventional secretion with aggregate export.*
---
## Hypothesis 2: RAB27A/ALIX Lysosomal Exocytosis
### Specific Weaknesses
**1. Mechanistic contradiction with primary PIKFYVE function.** PIKFYVE inhibition causes lysosomal vacuolation and blocks lysosome-autophagosome fusion (PMID: 22990836). If lysosomes are functionally impaired by the treatment, the premise that they undergo exocytosis at the plasma membrane is paradoxical—degraded PI(3,5)P2 lysosomes should be fusion-defective at all membranes.
**2. ALIX recruitment is ESCRT-III-dependent, not PI(3,5)P2-dependent.** ALIX is recruited to endosomes via Bro1 domain interactions with CHMP4B/ESCRT-III (PMID: 16903783), not via PI(3,5)P2. The claim that PI(3,5)P2 depletion "relieves inhibition" of ALIX lacks any demonstrated lipid-protein interaction or regulatory mechanism.
**3. The model assumes lysosomes are loaded with aggregates.** Lysosomes in motor neurons would have limited access to nuclear cytoplasmic aggregates. The "docking" of ubiquitinated aggregates to late endosomes via ALIX (PMID: 16903783) is for degradation in multivesicular bodies, not for plasma membrane exocytosis.
### Counter-Evidence
**1. ALIX loss-of-function causes neurodegeneration, not protection.** Mutations in *PDCD6IP* (ALIX) are associated with neurodegenerative phenotypes in models of tauopathy (PMID: 29189420), and ALIX knockdown exacerbates protein aggregate accumulation rather than clearing it.
**2. RAB27A is dispensable for lysosomal exocytosis in most cell types.** RAB27A specifically controls melanosome secretion in melanocytes and lytic granule release in cytotoxic T cells (PMID: 15102840). In most non-specialized cells, lysosomal exocytosis is RAB27A-independent and primarily controlled by RAB3 and RAB2 (PMID: 22573891).
**3. Endosomal accumulation of ubiquitinated aggregates is a hallmark of *impaired* secretion.** In ALS, ubiquitinated aggregates on late endosomes represent defective endosomal sorting that correlates with disease progression (PMID: 32873930), not functional clearance.
### Alternative Explanations
- **Lysosomal exocytosis of proteases** (cathepsins) without aggregates, altering extracellular environment
- **Bulk plasma membrane repair response** to PIKFYVE-induced vacuolar damage, releasing trapped cytoplasmic contents
- **Secretory autophagy** where autophagosomes directly fuse with plasma membrane (PMID: 25468908) independent of ALIX/RAB27A
### Key Experiments to Falsify
1. **Subcellular fractionation during PIKFYVE inhibition:** Isolate plasma membrane, late endosomes, and autophagosomes and determine whether aggregates are enriched in plasma membrane fractions (indicating exocytosis) or remain in endosomal fractions (indicating impaired degradation).
2. **RAB27A CRISPR knockout in motor neurons:** If PIKFYVE inhibition still clears aggregates in RAB27A-null cells, the hypothesis is falsified.
3. **Total internal reflection fluorescence (TIRF) microscopy:** Visualize lysosome-plasma membrane fusion events in real time during PIKFYVE inhibition. If lysosomal exocytosis events do not increase, the hypothesis fails.
### Revised Confidence: 0.28
*Rationale: The hypothesis requires lysosomes to be simultaneously fusion-defective (blocked autophagosome-lysosome fusion) and fusion-competent (plasma membrane exocytosis). No mechanism connects PI(3,5)P2 depletion to RAB27A activation. RAB27A is cell-type restricted and ALIX promotes degradation, not secretion.*
---
## Hypothesis 3: CHCHD10/Mitochondrial-Derived Vesicle Exocytosis
### Specific Weaknesses
**1. CHCHD10 loss-of-function causes ALS; blocking release should be protective.** This is the most fundamental flaw. CHCHD10 mutations cause ALS through loss-of-function mechanisms (OPA1-like mitochondrial fragmentation and cristae disruption) (PMID: 25261932). The hypothesis proposes that *releasing* CHCHD10 from mitochondria upon PIKFYVE inhibition is therapeutic—but this would further deplete mitochondrial CHCHD10, worsening mitochondrial dysfunction. The therapeutic logic is inverted.
**2. MDVs have no established exocytosis pathway.** Mitochondrial-derived vesicles fuse with lysosomes for degradation (PMID: 23870199), not with autophagosomes for secretion. The "MDVs fuse with autophagosomes and are exocytosed" pathway is not described in any primary literature.
**3. "Selective protection of mitochondria" may be artifactual.** The cited source (PMID: 36754049) may report preserved mitochondrial morphology in PIKFYVE-inhibited cells, but this is likely because impaired lysosomal acidification prevents mitophagy. Preserved mitochondria in this context means mitochondria that *cannot be degraded*, which is not the same as protected mitochondria.
### Counter-Evidence
**1. CHCHD10 aggregates in ALS are mitochondrial, not secretable.** CHCHD10 mutations lead to mitochondrial protein aggregation within mitochondria (PMID: 25261932), not to cytosolic aggregates suitable for exocytosis.
**2. PIKFYVE inhibition impairs mitochondrial quality control.** Since PIKFYVE is essential for lysosomal function, PIKFYVE inhibition would block mitophagy, making the claim of "mitochondrial-derived vesicle" quality control paradoxical—why produce MDVs if the lysosome that receives them is impaired?
**3. PI(3,5)P2 depletion does not specifically promote CHCHD10 phosphorylation.** No kinases regulated by PI(3,5)P2 have been demonstrated to phosphorylate CHCHD10. Casein kinase 2 (CK2) phosphorylates CHCHD10 (PMID: 26083769), but CK2 is not PI(3,5)P2-regulated.
### Alternative Explanations
- **Compensatory upregulation of mitochondrial biogenesis** (PGC-1α) in response to PIKFYVE inhibition
- **ER-mitochondria contact site remodeling** redirecting misfolded proteins to ER-associated degradation (ERAD)
- **TNF receptor-associated protein degradation** (TRADD pathway) unrelated to MDVs
### Key Experiments to Falsify
1. **CHCHD10 immunocytochemistry during PIKFYVE inhibition:** Does CHCHD10 actually relocalize from mitochondria to late endosomes? Mitochondrial fractionation and western blot would directly test this.
2. **CRISPR knock-in of phospho-mimetic vs. phospho-dead CHCHD10:** If CHCHD10 that cannot leave mitochondria blocks PIKFYVE inhibitor benefits, the hypothesis is supported. If both mutants permit therapeutic benefit, the hypothesis is falsified.
3. **MDV inhibitor experiment:** Treat cells with glyburide (an MDV inhibitor, PMID: 23870199) and determine whether PIKFYVE inhibition loses therapeutic benefit. If glyburide has no effect, the MDV hypothesis is falsified.
### Revised Confidence: 0.19
*Rationale: The hypothesis requires therapeutic benefit from depleting a neuroprotective mitochondrial protein, invokes a non-existent exocytic MDV pathway, and may misinterpret preserved mitochondria as protected mitochondria.*
---
## Hypothesis 4: YKT6 SNARE Fusion
### Specific Weaknesses
**1. Proposed SNARE complex is non-standard.** YKT6 typically forms SNARE complexes with SNAP29 and STX17 (not STX4) for ER-Golgi and mitochondrial trafficking (PMID: 29107332). The proposed SNAP23-STX4 complex is the canonical complex for regulated exocytosis of secretory granules, not unconventional secretion. These SNAREs do not typically interact with YKT6.
**2. PI(3,5)P2 depletion does not specifically alter SNARE dynamics.** The cited lipid alteration (PMID: 29273643) discusses general effects on membrane curvature and trafficking, not specific SNARE complex remodeling. No direct evidence links PI(3,5)P2 depletion to YKT6 palmitoylation or relocalization.
**3. Organelle identity problem.** "Plasma membrane-lysosome hybrid organelles" are not well-characterized in motor neurons and represent an unusual membrane biology premise. Lysosomes do not typically fuse with the plasma membrane in hybrid states.
### Counter-Evidence
**1. YKT6 is primarily ER/Golgi-localized, not plasma membrane-associated.** Super-resolution microscopy studies show YKT6 on ER sheets and Golgi (PMID: 29107332). Its plasma membrane association in unconventional secretion is transient and not well-characterized.
**2. PIKFYVE inhibition impairs general secretion.** Vacuolation caused by PIKFYVE inhibition disrupts organelle architecture broadly (PMID: 22990836). If the general secretion machinery were intact enough for SNARE-mediated exocytosis, vacuolation would not occur.
**3. YKT6-mediated unconventional secretion is for soluble proteins, not aggregates.** Leaderless proteins secreted via YKT6 (IL-1β, HMGB1) are soluble monomers (PMID: 29107332). Aggregated proteins cannot be packaged into conventional secretory vesicles due to size constraints.
### Alternative Explanations
- **Ceramide-dependent non-lytic viral-like egress** via ATPase-mediated membrane blebbing
- **Exosome biogenesis** from multivesicular bodies (which do depend on SNAREs but via ESCRT-dependent pathways)
- **ER-derived autophagosome formation bypassing Golgi** entirely
### Key Experiments to Falsify
1. **YKT6 CRISPR knockout or SUMOylation-dead mutant:** Test whether YKT6 loss-of-function blocks PIKFYVE inhibitor-mediated aggregate clearance. Note: YKT6 is essential for cell viability in some contexts, so conditional knockout is required.
2. **Biochemical characterization of exocytosed material:** Collect conditioned media from PIKFYVE-inhibited motor neurons and perform mass spectrometry. If aggregates are exocytosed, both the protein components and intact SNARE complexes should be detectable.
3. **Rescue with YKT6 variants:** Does expressing YKT6 without the palmitoylation site (C2 domain mutant) or with constitutive plasma membrane targeting restore or block the effect? This tests the relocalization requirement.
### Revised Confidence: 0.25
*Rationale: YKT6-mediated unconventional secretion handles soluble monomers. The proposed SNARE complex (YKT6-SNAP23-STX4) is not a known combination. PI(3,5)P2 depletion typically causes vacuolation that would impair SNARE-mediated fusion.*
---
## Hypothesis 5: Microglial STX11 Granule Exocytosis
### Specific Weaknesses
**1. Granule exocytosis releases granzymes for *cell killing*, not protein degradation.** Cytolytic granule exocytosis is designed to induce apoptosis in target cells (PMID: 16177804). This mechanism cannot degrade extracellular protein aggregates. The "piggyback" mechanism implies granules contain proteases that would be effective extracellularly, but granzymes (serine proteases) function *intracellularly* after receptor-mediated endocytosis.
**2. STX11 knockout is not associated with aggregate clearance phenotypes.** STX11 mutations cause familial hemophagocytic lymphohistiocytosis (HLH) (PMID: 16177804), a hyperinflammatory syndrome. No study links STX11 to protein aggregate homeostasis.
**3. Non-cell-autonomous mechanisms require systemic administration models.** If PIKFYVE inhibition acts primarily via microglia, motor neuron cultures (typically enriched for neurons only) would show no benefit. The therapeutic effect must be demonstrated in mixed cultures and *in vivo*.
### Counter-Evidence
**1. STX11 is primarily on endosomes, not secretory granules.** STX11 in microglia is associated with phagosome maturation and fusion with lysosomes (PMID: 24501467), not granule exocytosis. Its role in microglia is consistent with phagolysosomal function, not cytotoxic granule release.
**2. Microglial P2RX7 and P2Y12 receptors, not granule exocytosis, mediate aggregate clearance.** Purinergic receptor-mediated microglial phagocytosis (PMID: 28753427) is the established mechanism for debris clearance, not granule exocytosis.
**3. PIKFYVE inhibition in non-myeloid cells shows therapeutic benefit.** If the primary mechanism were microglial, neuronal-specific PIKFYVE inhibition should have no benefit—which is not what the literature suggests.
### Alternative Explanations
- **Autocrine/paracrine signaling via P2RX7 activation** (triggered by extracellular ATP from dying neurons) promoting microglial phagocytosis
- **Neprilysin and IDE upregulation** in microglia for extracellular aggregate degradation
- **TREM2-dependent phagocytosis** enhancement (TREM2 variants are major ALS/FTD risk factors, PMID: 27974619)
### Key Experiments to Falsify
1. **Microglia-specific PIKFYVE CRISPR knockout in ALS mice (SOD1, TDP-43):** If selective microglia PIKFYVE deletion is *sufficient* for therapeutic benefit, the hypothesis is supported. If only neuronal deletion is effective, the hypothesis is falsified.
2. **STX11 knockout in microglia co-culture:** Does deleting STX11 in microglia (but not motor neurons) prevent the therapeutic benefit of PIKFYVE inhibition? Use microfluidic compartmentalized cultures.
3. **Adoptive transfer of PIKFYVE-inhibited vs. control microglia:** Does transfer of PIKFYVE-inhibited microglia into ALS mice provide therapeutic benefit? If no benefit is observed, the hypothesis fails.
### Revised Confidence: 0.22
*Rationale: STX11-mediated granule exocytosis is not a protein aggregate clearance mechanism. The hypothesis requires cell-type specificity that is not supported by established microglial biology or PIKFYVE expression patterns.*
---
## Hypothesis 6: HSP90B1 ERES Formation
### Specific Weaknesses
**1. ERES formation is definitionally COPII-dependent.** ER exit sites require SEC12-catalyzed SAR1-GTP loading, SEC23/SEC24 coat formation, and SEC13/SEC31 lattice assembly. The claim of "ERES independent of COPII" contradicts the fundamental biochemistry of ER export.
**2. HSP90B1 is an ER lumen chaperone, not an ERES nucleator.** HSP90B1 (GRP94) resides in the ER lumen and chaperonesfolded proteins (PMID: 29987195). It has no demonstrated function in organizing membrane structures at the cytosolic face where ERES form.
**3. Aggregates in ER-derived vesicles would not be secreted in native form.** Even if misfolded proteins entered ER-derived vesicles, they would transit through the cis-Golgi where ER-resident proteins are normally retained. Without specific signals, aggregates would be detected and degraded by ER quality control.
### Counter-Evidence
**1. TFG mutations cause neuropathy by *impairing* ER export, not enhancing secretion.** TFG mutations cause hereditary spastic paraplegia 57 through disrupted ERES organization and impaired ER-Golgi trafficking (PMID: 23091053). This supports TFG being required for normal secretion, not unconventional export.
**2. SEC16A marks canonical ERES, not unconventional ones.** If PIKFYVE inhibition recruits SEC16A to autophagosomes, this would indicate canonical ERES are being redirected for ER-phagy, not that unconventional ERES are forming for secretion.
**3. PIKFYVE inhibition typically *activates* ERAD, not unconventional secretion.** The ER stress response to PIKFYVE inhibition (PMID: 28704975) would activate ERAD ( dislocation to cytoplasm and proteasomal degradation), not redirect proteins to alternative secretory pathways.
### Alternative Explanations
- **ER-phagy** via FAM134B, RTN3, or CCPG1 receptors delivering ER portions to autophagosomes (PMID: 30104642)
- **ER stress-induced autophagy** bypassing lysosomal fusion defects via autophagosome-lysosome-independent pathways
- **Golgi-independent trafficking via ER-derived vesicles** for specific cargo (e.g., ATG9A vesicles)
### Key Experiments to Falsify
1. **SEC16A and LC3B colocalization during PIKFYVE inhibition:** If canonical ERES are not being recruited to autophagosomes, the hypothesis is weakened.
2. **HSP90B1 knockout or inhibition:** Does HSP90B1 deletion block the therapeutic benefit? If PIKFYVE inhibition is still effective without HSP90B1, the hypothesis is falsified.
3. **Propose direct COPII-independent ER export assay:** Microsome-based reconstitution with Sar1A/T39N (dominant-negative COPII) to determine whether aggregates can enter ER-derived vesicles without SEC23-dependent COPII assembly.
### Revised Confidence: 0.24
*Rationale: The hypothesis requires ERES formation "independent of COPII" despite no known mechanism for this, and invokes HSP90B1 (a lumenal chaperone) as a membrane-nucleating protein. TFG mutations suggest disrupted export, not enhanced secretion.*
---
## Hypothesis 7: Annexin A2/S100A10 Extracellular Degradation
### Specific Weaknesses
**1. This is not a mechanism of exocytosis.** Annexin A2/S100A10-mediated extracellular protein clearance is distinct from exocytosis hypotheses and should be considered separately. The title explicitly addresses "exocytosis," but this hypothesis describes extracellular proteolysis, which is fundamentally different.
**2. Annexin A2 would itself need to be secreted.** Annexin A2 (37 kDa) lacks a signal peptide and is secreted via unconventional pathways (PMID: 24043799). If PIKFYVE inhibition does not enhance Annexin A2 secretion, the mechanism cannot proceed.
**3. Extracellular proteases require prior secretion of aggregates.** For Annexin A2 to degrade extracellular aggregates, aggregates must first be *released* from cells—requiring an exocytosis mechanism. This hypothesis does not provide the exocytosis component; it is downstream of it.
### Counter-Evidence
**1. Annexin A2 knockout mice are viable with minimal proteostasis phenotypes.** Annexin A2-null mice show defects in fibrinolysis and membrane repair (PMID: 24043799), but no studies report widespread protein aggregate accumulation, suggesting Annexin A2 is not a primary mediator of aggregate clearance.
**2. Annex